Omalizumab in patients with severe and refractory solar urticaria: A phase II multicentric study - 16/02/16
on behalf of the
Société Française de Photodermatologie
Supported by a grant from Novartis Pharma. Omalizumab was provided free of charge by Novartis Pharma. The funders had no role in the study design or performance, manuscript writing, or decision to publish. |
|
Disclosure: Dr Viguier received consulting fees, travel support, and payment for lectures from Novartis Pharma. Drs Aubin, Avenel-Audran, Adamski, and Marguery received travel support from Novartis Pharma. Drs Jeanmougin, Peyron, and Léonard, and Mr Puyraveau have no conflicts of interest to declare. |
|
Presented as a poster in the European Academy of Dermatology and Venereology Meeting in Copenhagen, Denmark, October 7-11, 2015. |
Vol 74 - N° 3
P. 574-575 - mars 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?